Short communication · 30 Jun 2026
PerspectivePublished 2 May 2022
Cutaneous Small Vessel Vasculitis Due to Dolutegravir: A Rare Side Effect of Dolutegravir Based HAART Regimen in PLHIV
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
According to World Health Organization (WHO), Dolutegravir-based regimen is considered as first-line therapy for PLHIV and strongly recommended for all adults and children at the 10th International AIDS Society Conference on HIV Science (IAS 2019) held in Mexico City. Dolutegravir (integrase inhibitor) is pharmacokinetically favorable with a single daily dose, fewer drug interactions, superior potency against HIV-1, and potency against efavirenz-resistant virus. In 2020, NACO announced the phase-wise replacement of TLE regimen to TLD regimen.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Vasculitis.
Case series · 31 Dec 2025
Thrombotic Vasculitis Case Series with a Discussion on Anticoagulation Strategies
Brief report · 29 Dec 2025
Endothelial Cell Dysregulation: Key to Rare Vascular Anomalies
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Vasculitis
- BylineArticles whose byline prints “Cutaneous small-vessel vasculitis”
- BylineArticles whose byline prints “Efavirenz-resistant virus”
- BylineArticles whose byline prints “Cutaneous examination”
- BylineArticles whose byline prints “Leukocytoclastic vasculitis”
